Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NYSE | Common Stock
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide.
The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International.
It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products.
The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases.
It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015.
Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland.
As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 19 | 5.22 Increased by +140.68% | 4.57 Increased by +14.22% |
| Sep 30, 19 | 4.25 Increased by +3.90 K% | 4.22 Increased by +0.71% |
| Jun 30, 19 | 4.38 Increased by +414.34% | 4.35 Increased by +0.69% |
| Mar 31, 19 | 3.79 Increased by +481.40% | 3.55 Increased by +6.76% |
| Jan 29, 19 | -12.83 Decreased by -247.84% | 4.15 Decreased by -409.20% |
| Oct 30, 18 | -0.11 Increased by +99.07% | 4.04 Decreased by -102.77% |
| Jul 26, 18 | -1.39 Increased by +41.29% | 4.13 Decreased by -133.74% |
| Apr 30, 18 | -0.99 Increased by +87.36% | 3.36 Decreased by -129.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 20 | 3.60 B Increased by +0.20% | 378.00 M Increased by +115.70% | Increased by +10.49% Increased by +115.67% |
| Dec 31, 19 | 4.35 B Increased by +6.65% | -317.20 M Increased by +92.62% | Decreased by -7.29% Increased by +93.08% |
| Sep 30, 19 | 4.05 B Increased by +3.56% | -786.80 M Decreased by -1.98 K% | Decreased by -19.42% Decreased by -1.90 K% |
| Jun 30, 19 | 4.09 B Decreased by -0.83% | -1.76 B Decreased by -272.28% | Decreased by -43.01% Decreased by -275.38% |
| Mar 31, 19 | 3.60 B Decreased by -2.04% | -2.41 B Decreased by -741.66% | Decreased by -66.94% Decreased by -759.21% |
| Dec 31, 18 | 4.08 B Decreased by -5.70% | -4.30 B Decreased by -237.76% | Decreased by -105.40% Decreased by -246.08% |
| Sep 30, 18 | 3.91 B Decreased by -3.05% | -37.90 M Increased by +99.04% | Decreased by -0.97% Increased by +99.01% |
| Jun 30, 18 | 4.12 B Increased by +2.91% | -472.50 M Increased by +34.91% | Decreased by -11.46% Increased by +36.75% |